Today in molecular mechanisms of immunosuppressive drugs actions: Roles of pharmacist;Mécanismes moléculaires de l'activité des immunosuppresseurs actuels en transplantation : rôles du pharmacien

Annales Pharmaceutiques Francaises

Volumn 66, Issue 2, 2008, Pages 102-114

  Hulin, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute rejection; Antimetabolites; Calcineurin inhibitors; Chronic rejection; Immunosuppressive drugs; mTOR inhibitors

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOCYTE ANTIBODY; LYMPHOGLOBULINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE ACETATE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL CYCLE REGULATION; CELLULAR IMMUNITY; DRUG MECHANISM; DRUG MONITORING; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MITOSIS INHIBITION; NEPHROTOXICITY; ORGAN DONOR; PATIENT EDUCATION; PHARMACIST ATTITUDE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; PHARMACIST; REVIEW;

DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT EDUCATION AS TOPIC; PHARMACISTS;

EID: 50649103767     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2008.03.005     Document Type: Article

References (83)

1. Abbas A.K., Lichtman A., and Pober J. Cytokines. Cellular and molecular immunology. 2nd ed. (1994), Saunders, Philadelphia 239-60
2. Cho YW, Terasaki PI. Long-term survival. In: Clinical transplants. Los Angeles: Terasaki PI ed; 1989. p. 277-82.
3. Busson M., Raffoux C., and Bouteiller A.M. Influence of HLA-A, B, and DR matching on the outcome of kidney transplant survival in preimmunized patients. Transplant 38 (1984) 227-230
4. Abbas A.K., Lichtman A., and Pober J. Immune response to tissue transplants. Cellular and molecular immunology (1994), Saunders, Philadelphia p. 335-7
5. Shimizu A., and Colvin R.B. Pathological features of antibody-mediated rejection. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 199-214
6. Baldwin W.M., Ota H., and Rodriguez E.R. Complement in transplant rejection: diagnostic and mechanistic considerations. Springer Semin Immunopathol 25 (2003) 181-197
7. Vierling J.M. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg 5 (1999) S1-S20
8. International Working Party. Terminology for hepatic allograft rejection. Hepatology 22 (1995) 648-654
9. Sharma V.K., Bologa R.M., Li B., Xu G.P., Lagman M., Hiscock W., et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplant 62 (1996) 1860-1866
10. Azuma H., and Tilney N.L. Chronic graft rejection. Curr Opin Immunol 6 (1994) 770-776
11. Fellstrom B., Holdaas H., Jardine A.G., Nyberg G., Gronhagen-Riska C., Madsen S., et al. Risk factors for reaching renal endpoints in the assessment of lescol in renal transplantation (ALERT) trial. Transplant 79 (2005) 205-212
12. Ventura H.O., Mehra M.R., Smart F.W., and Stapleton D.D. Cardiac allograft vasculopathy: current concepts. Am Heart J 129 (1995) 791-799
13. van Furth R. Human monocytes and cytokines. Res Immunol 149 (1998) 719-720
14. Germain R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76 (1994) 287-299
15. Almond P.S., Matas A., Gillingham K., Dunn D.L., Payne W.D., Gores P., et al. Risk factors for chronic rejection in renal allograft recipients. Transplant 55 (1993) 752-757
16. Lebranchu Y. Transplantation d'organes. Rev Prat 54 (2004) 2295-2304
17. Joosten S.A., van Kooten C., and Paul L.C. Pathogenesis of chronic allograft rejection. Transpl Int 16 (2003) 137-146
18. Massy Z.A., Guijarro C., Wiederkehr M.R., Ma J.Z., and Kasiske B. Chronic renal allograft rejection: immunologic and non immunologic risk factors. Kidney Int 49 (1996) 518-524
19. Michaels P.J., Fishbein M.C., and Colvin R.B. Humoral rejection of human organ transplants. Springer Semin Immunopathol 25 (2003) 119-140
20. Lebranchu Y. Mécanismes immunologiques de la dysfonction chronique du greffon. Courr Transplant 2 (2002) 20-27
21. Basadonna G.P., Matas A.J., Gillingham K., and Almond P.S. Early versus late acute allograft rejection: impact on chronic rejection. Transplant 55 (1993) 993-995
22. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. Transplant Proc 29 (1997) 73-76
23. Hullet D.A., Geraghty J.G., Stoltenberg R.L., and Sollinger H.W. The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Transplant 62 (1996) 1842-1846
24. Madsen J.C., Yamade K., and Allan J.S. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplant 65 (1998) 304-313
25. Akyurek L.M., Johnsson C., and Lange D. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants: influence of Fas-mediated apoptosis. J Clin Invest 101 (1998) 2889-2899
26. Sayeg M.H., and Turka L.A. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 6 (1995) 1143-1150
27. Russel M.E., Hancock W.H., and Akalin E. Chronic cardiac rejection in the LEW to F344 rat model. J Clin Invest 97 (1996) 833-838
28. Glysing-Jensen T., Raisanen-Sokolowski A., Sayegh M.H., and Russel M.E. Chronic blockade of CD28-B7-mediated-T-cell costimulation by CTLA-4-Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplant 64 (1997) 1641-1645
29. Chandraker A., Azuma H., and Nadeau K. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 101 (1998) 2309-2318
30. Male D., Champion B., and Cooke A. Advanced immunology. 2nd ed. (1991), Lippincott, Philadelphia
31. Halloran P.F., Broski A.P., Batiuk T.D., and Madrenas J. The molecular immunology of acute rejection: an overview. Transpl Immunol 1 (1993) 3-27
32. Serfling E., Avots A., and Neumann M. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta 1263 (1995) 181-200
33. Feske S., Giltnane J., Dolmetsch R., Staudt L.M., and Rao A. Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol 2 (2001) 316-324
34. Partiseti M., Le Deist F., Hivroz C., Fischer A., Korn H., and Choquet D. The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. J Biol Chem 269 (1994) 32327-32335
35. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 19 (2001) 497-521
36. Timmerman L.A., Clipstone N.A., Ho S.N., Northrop J.P., and Crabtree G.R. Rapid shuttling of NFAT in discrimination of Ca2+ signals and immunosuppression. Nature 383 (1996) 837-840
37. Loh C., Carew J.A., Kim J., Hogan P.G., and Rao A. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol Cell Biol 16 (1996) 3945-3954
38. Chen L., Glover J.N., Hogan P.G., Rao A., and Harrison S.C. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392 (1998) 42-48
39. Shibasaki F., Price E.R., Milan D., and McKeon F. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NFAT4. Nature 382 (1996) 370-373
40. Loh C., Shaw K.T., Carew J., Viola J.P., Luo C., Perrino B.A., et al. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem 271 (1996) 10884-10891
41. Al-Daraji W.I., Grant K.R., Ryan K., Saxton A., and Reynolds N.J. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 118 (2002) 779-788
42. Zhu J., Shibasaki F., Price R., Guillemot J.C., Yano T., Dotsch V., et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 93 (1998) 851-861
43. Sheridan C.M., Heist E.K., Beals C.R., Crabtree G.R., and Gardner P. Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 277 (2002) 48664-48676
44. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., and Crabtree G.R. Nuclear export of NFATc enhanced by glycogen synthase kinase-3. Science 275 (1997) 1930-1934
45. Chow C.W., Rincon M., Cavanagh J., Dickens M., and Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278 (1997) 1638-1641
46. Werlen G., Jacinto E., Xia Y., and Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. Embo J 17 (1998) 3101-3111
47. Schaefer A., Magocsi M., Fandrich A., and Marquardt H. Stimulation of the Ca2+-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A. Biochem J 335 (1998) 505-511
48. Chen C.Y., Forman L.W., and Faller D.V. Calcium-dependent immediate-early gene induction in lymphocytes is negatively regulated by p21Ha-ras. Mol Cell Biol 16 (1996) 6582-6592
49. Camano J., and Hunter C.A. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 15 (2002) 414-429
50. Jamieson C., McCaffrey P.G., Rao A., and Sen R. Physiologic activation of T cells via the T cell receptor induces NF-kappa B. J Immunol 147 (1991) 416-420
51. Osborn L., Kunkel S., and Nabel G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A 86 (1989) 2336-2340
52. Olyaei A.J., de Mattos A.M., and Bennett W.M. Pharmacology of immunosuppressive drugs. Drugs Today (Barc) 34 (1998) 463-479
53. Galat A. Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem 216 (1993) 689-707
54. Dolinski K., Muir S., Cardenas M., and Heitman J. All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 94 (1997) 13093-13098
55. Mackrill J.J., O'Driscoll S., Lai F.A., and McCarthy T.V. Analysis of type 1 ryanodine receptor-12 kDa FK506-binding protein interaction. Biochem Biophys Res Commun 285 (2001) 52-57
56. Botos J., Xian W., Smith D.F., and Smith C.L. Progesterone receptor deficient in chromatin binding has an altered cellular state. J Biol Chem 279 (2004) 15231-15239
57. Syed F., Rycyzyn M.A., Westgate L., and Clevenger C.V. A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine 20 (2003) 83-90
58. Lee S.P., Hwang Y.S., Kim Y.J., Kwon K.S., Kim H.J., Kim K., et al. Cyclophilin binds to peroxiredoxins and activates its peroxidase activity. J Biol Chem 276 (2001) 29826-29832
59. Kung L., and Halloran P.F. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplant 70 (2000) 327-335
60. Clipstone N.A., and Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357 (1992) 695-697
61. Trushin S.A., Pennington K.N., Algeciras-Schimnich A., and Paya C.V. Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. J Biol Chem 274 (1999) 22923-22931
62. Hollaender G.A., Bierer B.E., and Burakoff A.J. Molecular mechanisms of immunosuppressive drugs: cyclosporin A, FK506, and rapamycin. In: Tilney N.L., Strom T.B., and Paul L. (Eds). Transplantation biology (1996), Lippincott-Raven, Philadelphia 657-671
63. Hollenberg S.M., Giguere V., Segui P., and Evans R.M. Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. Cell 49 (1987) 39-46
64. Ratajczak T., Ward B.K., and Minchin R.F. Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem 3 (2003) 1348-1357
65. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., and Baldwin A.S. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15 (1995) 943-953
66. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
67. Hricik D.E., Almawi W.Y., and Strom T.B. Trends in the use of glucocorticoids in renal transplantation. Transplant 57 (1994) 979-989
68. Bonnefoy-Berard N., Verrier B., Vincent C., and Revillard J.P. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunol 77 (1992) 61-67
69. Soulillou J.P. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 46 (1994) 540-553
70. Johnson K., Niblack G., Richie R., MacDonell R., Nylander W., Walker P., et al. Multicenter comparison of rejection reversal: rabbit anti-human lymphocyte serum versus horse anti-human lymphocyte globulin. Transplant Proc 21 (1989) 1734-1735
71. Chang T.W., Kung P.C., Gingras S.P., and Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?. Proc Natl Acad Sci U S A 78 (1981) 1805-1808
72. Karnitz L.M., and Abraham R.T. Cytokine receptor signaling mechanisms. Curr Opin Immunol 7 (1995) 320-326
73. Hoogenboom H.R., and Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 21 (2000) 371-378
74. Kelly P.A., Gruber S.A., Behbod F., and Kahan B.D. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 17 (1997) 1148-1156
75. Abraham R.T., and Wiederrecht J. Immunopharmacology of rapamycin. Annu Rev Immunol 14 (1996) 483-510
76. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., and Kapoor A. Global ARCC trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
77. Lu C.Y., Sicher S.C., and Vazquez M.A. Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies. J Am Soc Nephrol 4 (1993) 1239-1256
78. Krensky A.M., and Clayberger C. Transplantation immunology. Pediatr Clin North Am 41 (1994) 819-839
79. Crabtree G.R., and Clipstone N.A. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63 (1994) 1045-1083
80. Allison A.C., and Eugui E.M. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 25 (1993) 8-18
81. Carr S.F., Papp E., Wu J.C., and Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 268 (1993) 27286-27290
82. Watson C.J., Bradley J.A., Friend P.J., Firth J., Taylor C.J., Bradley J.R., et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 5 (2005) 1347-1353
83. Calne R.Y. Prope tolerance with alemtuzumab. Liver Transpl 11 (2005) 361-363